bapineuzumab
Bapineuzumab is a humanized monoclonal antibody that acts on the nervous system and may have potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma. However, in 2012 it failed to produce significant cognitive improvements in patients in two major trials, despite lowering key biomarkers of AD, amyloid brain plaque and hyperphosphorylated tau protein in CSF. — Wikipedia
Clinical trial activity
14 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 2005 (NCT00174525)
Timeline
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinBINDING AGENT
Beta amyloid A4 protein binding agent
Targets N-terminus of amyloid beta. Induces Fc receptor mediated fagocytosis of amyloid-beta peptide.
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
APP other
Targets N-terminus of amyloid beta. Induces Fc receptor mediated fagocytosis of amyloid-beta peptide.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBapineuzumab ↗
- ChEMBLCHEMBL2108576 ↗
Also known as
- 3d-6
- aab-001
- aab-001
- aab-001, humanized 3d-6 monoclonal antibody
- bapineuzumab
- bapineuzumab
- bapineuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01254773 | Phase 2 | Dec 1, 2010 | Johnson and Johnson, Pfizer |
| NCT00998764 | Phase 3 | Dec 1, 2009 | Pfizer |
| NCT00996918 | Phase 3 | Dec 1, 2009 | Pfizer |
| NCT00937352 | Phase 3 | Jul 1, 2009 | Johnson and Johnson, Pfizer |
| NCT00916617 | Phase 2 | Jun 1, 2009 | Johnson and Johnson, Pfizer |
| NCT00663026 | Phase 2 | Nov 1, 2008 | Pfizer |
| NCT00667810 | Phase 3 | Jun 1, 2008 | Pfizer |
| NCT00676143 | Phase 3 | Jan 1, 2008 | Pfizer |
| NCT00575055 | Phase 3 | Dec 1, 2007 | Johnson and Johnson, Pfizer |
| NCT00574132 | Phase 3 | Dec 1, 2007 | Johnson and Johnson, Pfizer |
| NCT00606476 | Phase 2 | Dec 1, 2006 | Johnson and Johnson |
| NCT00397891 | Phase 1 | Oct 1, 2006 | Pfizer |
| NCT00112073 | Phase 2 | Apr 1, 2005 | Johnson and Johnson, Pfizer |
| NCT00174525 | Phase 2 | Apr 1, 2005 | Pharmacology Research Institute, Pharmacology Research Institute, Northridge |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 12 | 7 | 3 | 2005 |
| Johnson and Johnson | For profit | 7 | 6 | 2 | 2005 |
| Pharmacology Research Institute | For profit | 1 | 1 | 1 | 2005 |
| Pharmacology Research Institute, Northridge | For profit | 1 | 0 | 1 | 2005 |